Trial Profile

A Phase 2 Open-label 12-Week Trial of Adjunctive Ganaxolone Treatment (Part A) in Tuberous Sclerosis Complex-related Epilepsy Followed by Long-term Treatment (Part B)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ganaxolone (Primary)
Indications Epilepsy; Tonic-clonic epilepsy; Tuberous sclerosis
Focus Proof of concept; Therapeutic Use
Acronyms CALM; TSC
Sponsors Marinus Pharmaceuticals

Most Recent Events

12 Sep 2024 According to a Marinus Pharmaceuticals media release, updated baseline patient demographics and characteristics will be presented at upcoming Investor & Analyst Day
27 Oct 2022 Status changed from active, no longer recruiting to completed.
26 Apr 2022 Results assessing ganaxolone (GNX) as add-on therapy for TSC-associated refractory epilepsy presented at the 74th Annual Meeting of the American Academy of Neurology 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com